ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.110,38
-0,16%
S&P 500
5.667,20
0,64%
US Dollar vs BRL
5,4264
-0,40%
Bitcoin
64.661,34
-0,29%
Brent Oil
83,315
-1,22%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Nightstar Therapeutics Plc ADS (NITE)

  7. Nightstar Therapeutics Plc ADS (NITE) Notícias

NITE

Nightstar Therapeutics Plc ADS (NITE)

Nightstar Therapeutics Plc ADS
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NITE
DataHoraFonteTítuloCódigoCompanhia
04/03/201908:35Dow Jones NewsBiogen to Buy Nightstar Therapeutics for $25.50 a ShareNASDAQ:NITENightstar Therapeutics Plc ADS
04/03/201904:01GlobeNewswire Inc.Nightstar Therapeutics plc reaches agreement to be acquired by BiogenNASDAQ:NITENightstar Therapeutics Plc ADS
14/02/201919:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NITENightstar Therapeutics Plc ADS
14/02/201918:47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NITENightstar Therapeutics Plc ADS
13/02/201919:57Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:NITENightstar Therapeutics Plc ADS
12/02/201912:33Edgar (US Regulatory)Schedule 13gNASDAQ:NITENightstar Therapeutics Plc ADS
04/01/201919:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NITENightstar Therapeutics Plc ADS
20/11/201820:07Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NITENightstar Therapeutics Plc ADS
13/11/201804:00GlobeNewswire Inc.Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Qu...NASDAQ:NITENightstar Therapeutics Plc ADS
08/11/201809:05GlobeNewswire Inc.Nightstar Therapeutics to Participate in Multiple Conferences in NovemberNASDAQ:NITENightstar Therapeutics Plc ADS
09/10/201810:41Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:NITENightstar Therapeutics Plc ADS
04/10/201807:05GlobeNewswire Inc.Nightstar Therapeutics to Present at Chardan Genetic Medicines ConferenceNASDAQ:NITENightstar Therapeutics Plc ADS
02/10/201817:05GlobeNewswire Inc.Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ OptionNASDAQ:NITENightstar Therapeutics Plc ADS
01/10/201807:05GlobeNewswire Inc.Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the MesaNASDAQ:NITENightstar Therapeutics Plc ADS
28/09/201817:05Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:NITENightstar Therapeutics Plc ADS
28/09/201807:15Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NITENightstar Therapeutics Plc ADS
27/09/201822:11GlobeNewswire Inc.Nightstar Announces Pricing of Public OfferingNASDAQ:NITENightstar Therapeutics Plc ADS
27/09/201807:08Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:NITENightstar Therapeutics Plc ADS
25/09/201817:25GlobeNewswire Inc.Nightstar Announces Proposed Public Offering of American Depositary SharesNASDAQ:NITENightstar Therapeutics Plc ADS
25/09/201817:22Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:NITENightstar Therapeutics Plc ADS
22/09/201812:57GlobeNewswire Inc.Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP PatientsNASDAQ:NITENightstar Therapeutics Plc ADS
13/09/201807:05GlobeNewswire Inc.Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of DirectorsNASDAQ:NITENightstar Therapeutics Plc ADS
13/08/201807:05GlobeNewswire Inc.Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business HighlightsNASDAQ:NITENightstar Therapeutics Plc ADS
07/08/201807:05GlobeNewswire Inc.Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare ConferenceNASDAQ:NITENightstar Therapeutics Plc ADS
14/06/201807:05GlobeNewswireNightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in ChoroideremiaNASDAQ:NITENightstar Therapeutics Plc ADS
06/06/201807:35GlobeNewswireNightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third...NASDAQ:NITENightstar Therapeutics Plc ADS
31/05/201807:30GlobeNewswireNightstar Therapeutics to Present at Jefferies 2018 Global Healthcare ConferenceNASDAQ:NITENightstar Therapeutics Plc ADS
15/05/201816:00Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:NITENightstar Therapeutics Plc ADS
02/05/201810:00GlobeNewswire Inc.Nightstar Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care ConferenceNASDAQ:NITENightstar Therapeutics Plc ADS
23/04/201807:30GlobeNewswireNightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual MeetingNASDAQ:NITENightstar Therapeutics Plc ADS
 Apresentando as notícias mais relevantes sobre:NASDAQ:NITE

Seu Histórico Recente

BOV
HAGA3
HAGA ON
BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
AMER3
Americanas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
COGN3
COGNA ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
VVEO3
CM Hospitalar ON
BOV
JFEN3
JOAO FORTES ON
BOV
AMAR3
LOJAS MARISA ON
BOV
HBOR3
HELBOR ON
BOV
GOLL4
GOL PN
BOV
BOBR4
BOMBRIL PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados